Some eye conditions keep coming back, no matter what doctors try. A new look at patients with a rare, recurring eye inflammation reveals a hidden split in the disease. This discovery could change how doctors choose treatments.
Imagine having eye pain and blurry vision that keeps returning. Each time, you need steroid treatments just to see clearly. This is the reality for people with Chronic Relapsing Inflammatory Optic Neuropathy (CRION).
It is a rare condition where the optic nerve—the cable connecting the eye to the brain—becomes inflamed repeatedly. Current treatments often rely on steroids, which can cause serious side effects over time. Finding a better, long-term solution is urgent.
The Hidden Split in the Disease
For years, doctors treated CRION as one condition. But recent research shows it might actually be two different problems with similar symptoms.
The key difference lies in a blood test. It looks for antibodies called MOG-IgG. These antibodies attack the protective coating of nerve fibers.
Some patients test positive for these antibodies. Others test negative. This study explored whether this difference changes how the disease behaves and how it responds to medicine.
How the Immune System Confuses the Eye
Think of the optic nerve like an electrical wire. It needs a protective coating called myelin to send signals fast. In CRION, the immune system mistakenly attacks this coating.
If you have the MOG-IgG antibodies, it’s like having a specific key that unlocks the door to inflammation. Without this key, the attack might come from a different direction.
This study suggests that the "key" (MOG-IgG) changes how the disease acts and which medicines work best.
Looking Back at Patient Cases
Researchers looked at 60 patients from six European hospitals. All had confirmed CRION. The median age was 33, and 70% were female.
They checked each patient’s blood for MOG-IgG antibodies. Then, they reviewed medical records to see how the disease progressed and which treatments helped.
They followed the patients for a long time to track relapses and vision changes.
Two Very Different Disease Patterns
The results showed clear differences between the two groups.
About 45% of patients tested positive for MOG-IgG. These patients tended to be older when the disease started. They also had more frequent relapses before treatment.
The MOG-positive group had a relapse rate of about 2 per year. The MOG-negative group had about 1 relapse per year.
MRI scans also showed differences. MOG-positive patients often had more extensive inflammation in the optic nerve. They also had higher levels of a brain chemical called interleukin-6, which drives inflammation.
But Here’s the Catch
The good news is that these differences help doctors choose the right medicine.
In MOG-positive patients, a specific monoclonal antibody therapy worked very well. This drug, called tocilizumab, lowered the relapse rate significantly. After treatment, the relapse rate dropped from 2 per year to nearly zero.
In MOG-negative patients, other drugs like rituximab and azathioprine showed promise. But the results were not as strong as in the MOG-positive group.
This doesn’t mean this treatment is available yet.
What Experts Are Saying
The study authors emphasize that CRION is not a single disease. It is a syndrome with distinct subgroups.
They argue that testing for MOG-IgG should be standard practice. Without it, doctors might choose a therapy that doesn’t work well for that specific patient.
This personalized approach could prevent unnecessary steroid use and protect vision long-term.
If you or a loved one has recurring optic neuritis, ask your doctor about MOG-IgG testing. Knowing your antibody status could open up more targeted treatment options.
However, tocilizumab is not a standard treatment for CRION yet. It is currently used for other conditions like rheumatoid arthritis. Using it for optic neuritis would be off-label and requires specialist supervision.
This study looked back at past patient records, so it cannot prove cause and effect. The sample size was also small, with only 60 patients.
Additionally, the study was done in specialized hospitals in Europe. Results might differ in other populations or settings.
Researchers need to confirm these findings in larger, prospective studies. They also want to test tocilizumab directly in MOG-positive CRION patients in a controlled trial.
If successful, this could lead to new treatment guidelines. For now, the study highlights the importance of personalized medicine in rare eye diseases.
